[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Dancey DR, Chamberlain DW, Krajden M, Palefsky J, Alberti PW, Downey GP: Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature. Chest; 2000 Oct;118(4):1210-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature.
  • Cidofovir, a nucleoside analog antiviral agent, has been used with moderate success in the treatment of juvenile laryngeal papillomatosis (JLP) by direct intralesional injection.
  • A 35-year-old woman with a history of JLP requiring multiple laser ablations of laryngeal papillomata each year presented with hemoptysis and was found on CT scan to have bilateral, multiple pulmonary nodules and cysts.
  • Molecular DNA typing of a biopsy specimen obtained from a laryngeal papilloma confirmed infection with human papilloma virus type 11.
  • She received 12 months of treatment with IV cidofovir followed by 9 months of combined treatmentwith IV cidofovir and subcutaneous interferon-alpha-2A.
  • This therapeutic regime resulted in a markedly decreased requirement for surgical removal of laryngeal papillomata, and CT scanning documented the regression of the lesions in the lung parenchyma that persisted after the discontinuation of therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cystic Adenomatoid Malformation of Lung, Congenital / complications. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Laryngeal Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papilloma / drug therapy
  • [MeSH-minor] Adult. Biopsy. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / diagnosis. Papillomavirus Infections / drug therapy. Papillomavirus Infections / virology. Tomography, X-Ray Computed. Tumor Virus Infections / complications. Tumor Virus Infections / diagnosis. Tumor Virus Infections / drug therapy. Tumor Virus Infections / virology

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11035700.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 35
  •  go-up   go-down


2. Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C: Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respir J; 2001 Apr;17(4):830-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b.
  • In contrast to uncomplicated juvenile laryngeal papillomas which may regress spontaneously, papillomatosis involving pulmonary parenchyma is associated with a poor outcome.
  • Bronchoscopy revealed polypoid lesions of the right vocal cord and the midtrachea which were confirmed as squamous papillomatosis by histology.
  • Interferon (IFN)alpha-2b treatment was inefficient as was cidofovir monotherapy on a maintenance basis.
  • Six months of IFN-alpha-2b and cidofovir in combination led to a complete macroscopic disappearance of the laryngeal lesions and to an impressive regression of the tracheal papillomas and of the intrapulmonary consolidations.
  • Probably the same mechanisms as in ribavirin plus interferon alpha-2b, in the treatment of patients with chronic hepatitis C, are responsible for the therapeutic success in this case.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Interferon-alpha / administration & dosage. Lung Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Injections, Intravenous. Laryngeal Neoplasms / drug therapy. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11401080.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 0 / Recombinant Proteins; 8J337D1HZY / Cytosine; 99210-65-8 / interferon alfa-2b; JIL713Q00N / cidofovir
  •  go-up   go-down


3. Xiao P, Zhang XS: Adult laryngotracheal surgery. Anesthesiol Clin; 2010 Sep;28(3):529-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human larynx plays a pivotal role in airway protection, respiration, and phonation.
  • Laryngeal disorders can be divided into two categories, benign lesions and malignant lesions.
  • Most benign lesions are treatable with surgery and speech therapy, whereas the malignant lesions require more invasive surgery as well as radiation and chemotherapy.
  • [MeSH-major] Anesthesia. Larynx / surgery. Trachea / surgery
  • [MeSH-minor] Adult. Anesthesia, General. Humans. Laryngeal Diseases / surgery. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Laryngectomy. Papilloma / surgery. Preoperative Care. Reconstructive Surgical Procedures. Tracheitis / surgery

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20850083.001).
  • [ISSN] 1932-2275
  • [Journal-full-title] Anesthesiology clinics
  • [ISO-abbreviation] Anesthesiol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, Lin DT: Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol; 2010 Jul-Aug;31(4):291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis.
  • OBJECTIVE: The objective is to present an uncommon case of squamous cell carcinoma (SCC) arising from extensive recurrent respiratory papillomatosis (RRP) involving the upper and lower airway and temporal bone.
  • METHODS: We describe a case of a 24-year-old woman with a history of human papillomavirus (HPV) type 11 since childhood originating in the larynx and trachea, then progressing to involve the distal pulmonary alveoli and right middle ear through the eustachian tube.
  • Papillomatous growth was treated with multiple surgeries including laser cytoreduction of laryngotracheal papillomatosis and radical mastoidectomy, followed by a trial of chemotherapy.
  • Despite this aggressive treatment regimen, papillomatous growth progressed with recurrence in the right eustachian tube, middle ear, and mastoid eventually extending to involve the calvaria and scalp.
  • RESULTS: The patient underwent a composite resection of involved tissues, including the scalp, auricle, and lateral temporal bone, with reconstruction using a latissimus dorsi free flap.
  • Final pathologic analysis revealed an extensive infiltrative well-differentiated SCC arising from the papilloma.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Human papillomavirus 11. Papilloma / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20015762.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Bielecki I, Mniszek J, Cofała M: Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children. Int J Pediatr Otorhinolaryngol; 2009 May;73(5):681-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Papillomatosis of the larynx appears as the result of an infection by the human papilloma virus (HPV).
  • There is currently no effective therapy for recurrent respiratory papillomatosis (RRP).
  • The basic goal of treatment is to preserve the patency of air passages while simultaneously preserving the phonatory and anatomical functioning of the larynx.
  • Over the last 10 years, the possibility of a pharmacological treatment has been continually explored: in particular, the administration of locally passed cidofovir (first reported in a 1999 study by Pransky) to the larynx with papillomas is under current scrutiny.
  • GOAL OF STUDY: The goal of the following study is to estimate the effectiveness of locally administered cidofovir for treatment of papillomas of the larynx in children.
  • RESULTS: Seven of the 10 patients achieved total remission 6 months after the completion of treatment, scoring 0 points on Derkay's scale.
  • These patients underwent therapy with cidofovir from 6 to 13 months.
  • Three months after the completion of treatment, three children suffered a recurrence of papillomas.
  • CONCLUSIONS: The results of the study indicate that intralesional injections of cidofovir can be an effective method of treatment for recurrent respiratory papillomatosis in children.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Injections, Intramuscular. Laryngeal Muscles. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193450.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


6. Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, Urba SG, Worden FP, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bradford CR, Carey TE: Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys; 2007;69(2 Suppl):S109-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking.
  • Induction chemotherapy and concurrent chemoradiation for responders or immediate surgery for non-responders is an effective treatment strategy head and neck squamous cell carcinoma (HNSCC) of the larynx and oropharynx.
  • Biomarkers that predict outcome would be valuable in selecting patients for therapy.
  • In this study, the presence and titer of high risk human papilloma virus (HPV) and expression of epidermal growth factor receptor (EGFR) in pre-treatment biopsies, as well as smoking and gender were examined in oropharynx cancer patients enrolled in an organ sparing trial.
  • HPV16 copy number was positively associated with response to therapy and with overall and disease specific survival, whereas EGFR expression, current or former smoking behavior, and female gender (in this cohort) were associated with poor response and poor survival in multivariate analysis.
  • Smoking cessation and strategies to target EGFR may be useful adjuncts for therapy to improve outcome in the cases with the poorest biomarker profile.

  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 1999 Nov;121(5):534-8 [10547465.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Head Neck. 2002 Sep;24(9):841-9 [12211048.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):336-44 [12569557.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2606-11 [16763272.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1096-104 [16020667.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5856-62 [16115926.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):593-8 [16380415.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7683-8 [15914551.001]
  • (PMID = 17848274.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA046592-150011; United States / NIDCR NIH HHS / DE / R01 DE013346-05; United States / NCI NIH HHS / CA / P50 CA097248-05; United States / NCI NIH HHS / CA / CA097248-03S1; United States / NCI NIH HHS / CA / P50 CA97248; United States / NCI NIH HHS / CA / P50 CA097248-010002; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / DE013346-04; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NCI NIH HHS / CA / CA083087-04; United States / NIDCR NIH HHS / DE / DE013346-02; United States / NCI NIH HHS / CA / CA046592-150011; United States / NCI NIH HHS / CA / CA097248-04; United States / NCI NIH HHS / CA / R01 CA083087; United States / NCI NIH HHS / CA / R01 CA083087-01; United States / NCI NIH HHS / CA / P50 CA097248-04S1; United States / NIDCR NIH HHS / DE / R01 DE013346-01S1; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / R01 CA083087-05; United States / NCI NIH HHS / CA / P50 CA097248-01; United States / NCI NIH HHS / CA / P30 CA046592-140011; United States / NCI NIH HHS / CA / R01 CA083087-02; United States / NCI NIH HHS / CA / P30 CA46592; United States / NCI NIH HHS / CA / CA046592-140011; United States / NCI NIH HHS / CA / R01 CA83087; United States / NCI NIH HHS / CA / CA097248-04S1; United States / NIDCR NIH HHS / DE / DE013346-03; United States / NCI NIH HHS / CA / CA097248-010002; United States / NCI NIH HHS / CA / CA097248-01; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NCI NIH HHS / CA / CA083087-03; United States / NCI NIH HHS / CA / P50 CA097248-04; United States / NCI NIH HHS / CA / CA097248-05; United States / NIDCR NIH HHS / DE / R01 DE013346-03; United States / NCI NIH HHS / CA / P50 CA097248-03S1; United States / NCI NIH HHS / CA / R01 CA083087-03; United States / NIDCR NIH HHS / DE / R01 DE013346-02; United States / NCI NIH HHS / CA / P50 CA097248-02; United States / NIDCR NIH HHS / DE / DE013346-03S1; United States / NCI NIH HHS / CA / CA083087-02; United States / NCI NIH HHS / CA / CA083087-01; United States / NCI NIH HHS / CA / CA097248-02; United States / NIDCD NIH HHS / DC / P30 DC05188; United States / NIDCR NIH HHS / DE / DE013346-01S1; United States / NIDCR NIH HHS / DE / R01 DE013346-04; United States / NIDCR NIH HHS / DE / DE013346-01; United States / NCI NIH HHS / CA / R01 CA083087-04; United States / NIDCR NIH HHS / DE / DE013346-05; United States / NCI NIH HHS / CA / P50 CA097248-03; United States / NIDCR NIH HHS / DE / R01 DE13346; United States / NIDCR NIH HHS / DE / R01 DE013346-01; United States / NCI NIH HHS / CA / CA097248-03; United States / NCI NIH HHS / CA / CA083087-05; United States / NIDCR NIH HHS / DE / R01 DE013346-03S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS30942; NLM/ PMC2084353
  •  go-up   go-down


7. Nowaczewska K, Wójtowicz P, Kukwa A, Ratajczak J, Tulibacki M: [Respiratory papillomatosis--new methods of treatment]. Otolaryngol Pol; 2010 Jan-Feb;64(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Respiratory papillomatosis--new methods of treatment].
  • The most common location in head and neck is larynx, palatine tonsils and arches of palate, uvula and mucosa oral and nasal cavity.
  • The aim of this study was to estimate new methods of treatment respiratory papillomatosis based on intralesional injection of cidofovir into sites where papillomas had just been excised.
  • The treatment was based on surgical excision of papilloma and after it intralesional injection of cidofovir in after 4-5 weeks.
  • 41 patients had 4 times intralesional injection of cidofovir.
  • 18 patients had increased number of injection of ciodofovir because of recurrent papilloma.
  • CONCLUSION: Surgery with intralesional cidofovir injection in the place after removal of papilloma is very effective methods.
  • We observed that this treatment caused long lasting remission of papilloma recurrence.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Male. Middle Aged. Neoplasm Staging. Poland. Remission Induction. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20476590.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


8. Savvides PP: The role of chemotherapy in the management of patients with head and neck cancer. Semin Plast Surg; 2010 May;24(2):137-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy in the management of patients with head and neck cancer.
  • Recent advances in the management of patients with head and neck cancer point to an expanding role of chemotherapy, resulting in an increased involvement of the medical oncologist in the multidisciplinary care of these patients.
  • This review focuses on patients with squamous cell carcinoma of the oral cavity, pharynx, and larynx.
  • Information on human papilloma virus-associated squamous cell cancer of the head and neck is presented, and implications in the clinical management of this subgroup of patients based on the epidemiologic and pathologic characteristics are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22550434.001).
  • [ISSN] 1535-2188
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3324245
  • [Keywords] NOTNLM ; Cancer of the head and neck / chemotherapy / squamous cell carcinoma
  •  go-up   go-down


9. Neumann K, Pudszuhn A, Welzel C, Bartel-Friedrich S, Passmann M: [Intralesional cidofovir injections for recurrent laryngeal papillomatosis: first results]. Laryngorhinootologie; 2003 Oct;82(10):700-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intralesional cidofovir injections for recurrent laryngeal papillomatosis: first results].
  • BACKGROUND: The treatment of recurrent laryngeal papillomatosis still presents an important therapeutic problem.
  • This primarily benign disease of the larynx is caused by an infection with the human papilloma virus (HPV) and forms epithelial neoplastic papillomas.
  • Therapy in larynx obstructing papillomatosis usually requires laser ablation.
  • Seven patients, age of five to 70 years, were treated with intralesional injections of Cidofovir after microlaryngoscopic ablation of laryngeal papillomas.
  • RESULTS AND CONCLUSIONS: After three to six sessions of laser ablation of the papillomas and intralesional injections with Cidofovir a distinct papilloma reduction could be observed in all patients and in two cases a complete remission was achieved.
  • The follow-up period of seven to 15 months revealed no recurrent laryngeal papillomatosis.
  • There were no local or systemic side-effects caused by the virustatic drug.
  • Intralesional injection of Cidofovir appears to develop into a promising adjuvant therapy option in recurrent laryngeal papillomatosis.
  • First results of the study seem to achieve a considerable reduction of the previously high rate of recurrence of laryngeal papillomatosis.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Airway Obstruction / drug therapy. Airway Obstruction / pathology. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Inclusion Bodies, Viral / drug effects. Inclusion Bodies, Viral / ultrastructure. Injections, Intralesional. Larynx / drug effects. Larynx / pathology. Larynx / surgery. Laser Therapy. Male. Microscopy, Electron. Middle Aged. Pilot Projects. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14593568.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


10. Wilson WR, Hashemiyoon R, Hawrych A: Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report. Ear Nose Throat J; 2000 Apr;79(4):236-8, 240
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report.
  • This is a preliminary report of an ongoing study to test the efficacy of intralesional injections of the antiviral drug cidofovir in adults with recurrent laryngeal papillomas in whom multiple other treatments have previously failed.
  • Biopsies of the lesion sites were obtained at the initiation and completion of therapy.
  • No other treatment was given.
  • Resolution of lesions was monitored by videolaryngoscopy and still photography 1 to 2 weeks after each treatment.
  • In time, the lesions resolved in all three patients, although all three later experienced a minor recurrence.
  • We conclude that intralesional cidofovir appears to be a promising new treatment for controlling--and perhaps at higher dosages curing--refractory laryngeal papillomas, while causing little or no injury to laryngeal structures.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adult. Clinical Protocols. Humans. Injections, Intralesional. Male. Middle Aged. Papillomaviridae / isolation & purification. Recurrence. Retreatment. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10786384.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


11. Bielamowicz S, Villagomez V, Stager SV, Wilson WR: Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope; 2002 Apr;112(4):696-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort.
  • OBJECTIVES: To confirm the safety and efficacy of intralesional cidofovir in the management of laryngeal papilloma and to identify variables that correlate with number of injections needed to achieve remission.
  • STUDY DESIGN: An open-trial prospective evaluation of the efficacy of intralesional cidofovir in subjects with laryngeal papilloma.
  • METHODS: Fourteen adult subjects with biopsy-proven laryngeal papilloma were enrolled in a treatment study of intralesional cidofovir.
  • Injections were repeated until no papilloma could be visually identified during an intraoperative evaluation.
  • RESULTS: All subjects have achieved disease remission using an injection-only treatment protocol.
  • No additional laryngeal scarring or systemic toxicity was identified.
  • CONCLUSIONS: Intralesional injection of cidofovir is an excellent treatment option with limited local and systemic toxicities.
  • The injection therapy regimen requires perseverance from both patient and surgeon.
  • Remission of disease can be achieved in adults with laryngeal papilloma.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / administration & dosage. Laryngeal Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Cohort Studies. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12150526.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


12. Schraff S, Derkay CS, Burke B, Lawson L: American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg; 2004 Sep;130(9):1039-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy.
  • OBJECTIVE: To evaluate how evolving treatment technologies have affected our management of recurrent respiratory papilloma (RRP) since the last comprehensive survey of pediatric otolaryngologists in 1998.
  • A total of 150 (21%) of these patients presently receive adjuvant medical therapies with cidofovir and interferon, accounting for more than two thirds of the total.
  • Distal spread of RRP has occurred in 94 (13%) of the 700 patients.
  • The laryngeal microdebrider (53%) has supplanted the carbon dioxide laser (42%) as the preferred means of surgically removing papilloma from the larynx in children.
  • Routine human papillomavirus subtyping is practiced by 45% of respondents while 15% treat all their patients with antireflux medications.
  • CONCLUSIONS: Recurrent respiratory papilloma continues to be a frustrating disease to treat and is associated with significant morbidity and mortality.
  • There has been an evolution in the past decade toward the increased use of antiviral adjuvant therapy and the use of microdebrider techniques for surgical management.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Australia. Chemotherapy, Adjuvant. Child. Child, Preschool. Debridement / methods. Europe. Health Care Surveys. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Microsurgery. North America. Organophosphorus Compounds / therapeutic use

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15381589.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


13. Major T, Sziklai I, Czeglédy J, Gáll T, Gergely L, Szarka K: Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis. Anticancer Res; 2008 Jul-Aug;28(4B):2169-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis.
  • BACKGROUND: Cidofovir is a cytosine nucleoside analogue antiviral drug given as an adjuvant therapy in recurrent respiratory papillomatosis (RRP).
  • MATERIALS AND METHODS: Intralesional cidofovir therapy was given to a 14-year-old male patient.
  • The papilloma severity score (PSS) of Derkay et al. was used for follow-up.
  • Serial fresh-frozen biopsies were taken from the lesions in the larynx and soft palate prior to therapy and during its course.
  • After human papillomavirus (HPV) typing and the determination of the genomic physical state, the HPV DNA copy number was estimated with real-time PCR.
  • RESULTS: All the papillomas harboured HPV 11 DNA in episomal form.
  • Prior to therapy, the HPV copy number fluctuated with time.
  • In the initial treatment period with 2-week-intervals both the viral load and the PSS decreased and a transient complete remission was observed.
  • CONCLUSION: The initial treatment period was successful, as the viral load decreased, and long-term effects of cidofovir might account for the controlled disease as the injection intervals were prolonged.
  • [MeSH-major] Cytosine / analogs & derivatives. DNA, Viral / genetics. Human papillomavirus 11 / genetics. Laryngeal Neoplasms / virology. Organophosphonates / therapeutic use. Papilloma / virology. Papillomavirus Infections / virology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Gene Dosage. Humans. Male. Mouth Neoplasms / drug therapy. Mouth Neoplasms / virology. Palate, Soft / pathology. Viral Load

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751391.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


14. Shehab N, Sweet BV, Hogikyan ND: Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy; 2005 Jul;25(7):977-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature.
  • Recurrent respiratory papillomatosis (RRP) is a rare but potentially severe disease caused by papillomavirus, most often types 6 and 11.
  • The disease, which occurs in both juvenile and adult forms, is characterized by benign epithelial tumors of the airway that most frequently affect the larynx but can also spread along the entire aerodigestive tract.
  • Recurrent respiratory papillomatosis is the most common benign neoplasm of the larynx in children and the second most frequent cause of childhood hoarseness.
  • Standard treatment, which is palliative only, consists of surgical excision of papillomata to maintain airway patency and improve voice quality.
  • To date, incorporation of adjuvant treatments has not been reliably beneficial in altering the disease course.
  • To evaluate the data available on the safety and efficacy of cidofovir for the treatment of RRP, we conducted a MEDLINE search for all case reports or series from January 1966-August 2004 describing cidofovir therapy in either adults or children with RRP.
  • Further studies are necessary to determine the most appropriate dose, frequency, and duration of therapy, and to fully characterize the safety profile profile of cidofovir when given intralesionally.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Child. Clinical Trials as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Male


15. Szyfter W, Wierzbicka M, Jackowska J, Bartochowska A, Banaszewski J: [The schedule of intralesional papillomatosis treatment with cidofovir]. Otolaryngol Pol; 2010 Mar-Apr;64(2):98-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The schedule of intralesional papillomatosis treatment with cidofovir].
  • It is characterized by proliferation of benign squamous cell papillomas within the respiratory-digestive tract, predominantly the larynx.
  • Standard treatment consists of surgical excision of papillomata to maintain airway patency and voice quality.
  • For last several years cidofovir is the most contemporary adjuvant anti-viral treatment for recurrent respiratory papillomatosis and its topical use is widely described.
  • MATERIAL AND METHODS: Intralesional cidofovir therapy was given to 20 patients treated for laryngeal papillomas in the Department of Otolaryngology in Poznan between I-XII.2009.
  • The number of cidofovir injections per patient varied from one to six times and the volume of solution ranges from 1-12 ml.
  • CONCLUSIONS: Intralesional cidofovir injection has been shown to be an effective an safe therapy for laryngeal papilloma and should be considered in those patients who experienced disease relapse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Poland. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568538.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


16. Elackattu AP, Feng L, Wang Z: A controlled safety study of diindolylmethane in the immature rat model. Laryngoscope; 2009 Sep;119(9):1803-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Diindolylmethane (DIM), a natural product from cruciferous vegetables, has been shown to be a dietary component that has inhibitory effects on some tumors (e.g., laryngeal papilloma).
  • METHODS: Forty rats were separated into four treatment groups of 10 rats each, based on the amount of study drug they received in their daily food:.
  • CONCLUSIONS: Diindolylmethane seems to have no adverse affects on the rat even when given in doses 3x what we propose to be therapeutic.
  • This adds evidence to the safety of this drug in the pediatric population as a treatment option for recurrent respiratory papilloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1161-72 [12479697.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2009 May;73(5):681-4 [19193450.001]
  • [Cites] J Voice. 2004 Jun;18(2):248-53 [15193659.001]
  • [Cites] J Toxicol Environ Health. 1987;21(3):311-23 [3495667.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):337-41 [8390800.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4569-73 [9891520.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):332-5 [15602729.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1320-7 [16385077.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4880-7 [16651444.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Sep;115(9):679-85 [17044539.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6502-11 [17616712.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Sep;137(3):477-81 [17765779.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):661-4 [18642764.001]
  • [Cites] In Vivo. 2008 Jul-Aug;22(4):441-5 [18712169.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2619-24 [18843002.001]
  • [Cites] J Nutr. 2009 Jan;139(1):26-32 [19056653.001]
  • [Cites] J Cell Physiol. 2009 Apr;219(1):94-9 [19062173.001]
  • [Cites] Toxicol Sci. 2003 Jul;74(1):10-21 [12730619.001]
  • (PMID = 19544380.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC008287-02; United States / NIDCD NIH HHS / DC / R01 DC008287; United States / NIDCD NIH HHS / DC / 5R01DC008287-02; United States / NIDCD NIH HHS / DC / R01 DC008287-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / diindolylmethane; 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS115765; NLM/ PMC3015182
  •  go-up   go-down






Advertisement